EA201200765A1 - Способ получения полиморфной модификации холиновой соли производного пиримидин-5-илуксусной кислоты - Google Patents

Способ получения полиморфной модификации холиновой соли производного пиримидин-5-илуксусной кислоты

Info

Publication number
EA201200765A1
EA201200765A1 EA201200765A EA201200765A EA201200765A1 EA 201200765 A1 EA201200765 A1 EA 201200765A1 EA 201200765 A EA201200765 A EA 201200765A EA 201200765 A EA201200765 A EA 201200765A EA 201200765 A1 EA201200765 A1 EA 201200765A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrimidin
iluxic
acid
salt derivative
polymorphic modification
Prior art date
Application number
EA201200765A
Other languages
English (en)
Inventor
Дхилип Кришнамёрти
Хуан-Мануэль Родригес-Дели
Михаэль Шуль
Сяоцзунь Ван
Биншио Ян
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43447007&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201200765(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201200765A1 publication Critical patent/EA201200765A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

В заявке описан способ получения холиновой соли [4,6-бис(диметиламино)-2-(4-{[4-(трифторметил)бензоил]амино}бензил)пиримидин-5-ил]уксусной кислоты. Предлагаемый в изобретении способ позволяет получать подобную соль в более чистой форме. В заявке описана также более чистая форма холиновой соли [4,6-бис-(диметиламино)-2-(4-{[4-(трифторметил)бензоил]амино}бензил)пиримидин-5-ил]уксусной кислоты.
EA201200765A 2009-11-24 2010-11-19 Способ получения полиморфной модификации холиновой соли производного пиримидин-5-илуксусной кислоты EA201200765A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26387109P 2009-11-24 2009-11-24
PCT/US2010/057312 WO2011066176A1 (en) 2009-11-24 2010-11-19 Process for preparing a polymorph of the choline salt of a pyrimidin-5-yl acetic acid derivative

Publications (1)

Publication Number Publication Date
EA201200765A1 true EA201200765A1 (ru) 2013-02-28

Family

ID=43447007

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200765A EA201200765A1 (ru) 2009-11-24 2010-11-19 Способ получения полиморфной модификации холиновой соли производного пиримидин-5-илуксусной кислоты

Country Status (16)

Country Link
US (1) US20110294828A1 (ru)
EP (1) EP2504319A1 (ru)
JP (1) JP2013512242A (ru)
KR (1) KR20120101399A (ru)
CN (1) CN102666499A (ru)
AR (1) AR079128A1 (ru)
AU (1) AU2010324980A1 (ru)
BR (1) BR112012012384A2 (ru)
CA (1) CA2781610A1 (ru)
CL (1) CL2012001170A1 (ru)
EA (1) EA201200765A1 (ru)
IL (1) IL218990A0 (ru)
MX (1) MX2012006003A (ru)
PH (1) PH12012500953A1 (ru)
TW (1) TW201200501A (ru)
WO (1) WO2011066176A1 (ru)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
DE3682457D1 (de) 1985-07-30 1991-12-19 Glaxo Group Ltd Geraet zur verabreichung von medikamenten an patienten.
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE60303238T2 (de) * 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
CA2659189A1 (en) 2006-08-03 2008-02-07 Bromine Compounds Ltd. Method, device and system for water treatment
JP6006914B2 (ja) * 2007-06-21 2016-10-12 アクチミス ファーマシューティカルズ インコーポレーテッド Ｃｒｔｈ２アンタゴニストのアミン塩
CN103172573A (zh) 2007-06-21 2013-06-26 艾克提麦斯医药品有限公司 Crth2 拮抗剂的微粒

Also Published As

Publication number Publication date
CL2012001170A1 (es) 2012-10-12
JP2013512242A (ja) 2013-04-11
KR20120101399A (ko) 2012-09-13
TW201200501A (en) 2012-01-01
IL218990A0 (en) 2012-06-28
CA2781610A1 (en) 2011-06-03
BR112012012384A2 (pt) 2016-03-22
AU2010324980A1 (en) 2012-05-03
MX2012006003A (es) 2012-06-19
EP2504319A1 (en) 2012-10-03
AR079128A1 (es) 2011-12-28
PH12012500953A1 (en) 2013-01-07
CN102666499A (zh) 2012-09-12
WO2011066176A1 (en) 2011-06-03
US20110294828A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
SMT201700529T1 (it) Metodi per un'aumentata produzione di proteine
AP2013007233A0 (en) l)-3-(trifluoromethyl phenylÜ benzamide solubilizeModified release of 4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]-N-5-(4-methyl-IH-imidazol-I-yd using organic acids
UA111640C2 (uk) ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
ECSP10010582A (es) Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer
EA201171065A1 (ru) Очистка 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
HUE056365T2 (hu) 2-(2,4,5-Helyettesített-anilino)pirimidin származékok
CY1115944T1 (el) Παραγωγα 4-(ινδολ-7-υλοκαρβονυλαμινομεθυλο)κυκλοεξανοκαρβοξυλικου οξεος ως ανταγωνιστες του ερ4 υποδοχεα χρησιμοι για την αντιμετωπιση χρονιας νεφρικης ανεπαρκειας ή διαβητικης νεφροπαθειας
UA84462C2 (ru) Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
DK3683209T3 (da) Fremgangsmåde til fremstilling af [(5-(3-chlorphenyl)-3-hydroxypyridin-2-carbonyl)-amino]eddikesyre fra 5-((3-chlorphenyl)-3-chlor-pyridin-2-yl)-nitril og fremgangsmåde til fremstilling af 5-((halogenphenyl)-3-halogen-pyridin-2-yl)-nitrilderivater
WO2012044727A3 (en) Manufacturing process for pyrimidine derivatives
EA200702614A1 (ru) Способы получения 4-(бифенилил)азетидин-2-оналкилфосфиновых кислот
EA201101301A1 (ru) Натриевая соль 5-циклопропил-2-{[2-(2,6-дифторфенил)пиримидин-5-ил]амино}бензойной кислоты в качестве ингибиторов dhodh
BRPI0905928A2 (pt) "método de produção de ácido lático"
EA201300990A1 (ru) Парентеральное введение тапентадола
WO2012042534A3 (en) Preparation of r-sitagliptin and intermediates thereof
CR20140462A (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil} amino) -1-hidroxietil]-8-hidroquinolin-2(1h)-ona
UA104420C2 (ru) Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств
ECSP10010597A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
SG10201902903RA (en) Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
BRPI0913644A2 (pt) processo para a prepração de derivados de pirimidina substituída.
SMT201400064B (it) Procedimento per la produzione di acido 2-[(3,5-difluoro-3'-metossi-1,1'-bifenil-4-il) amino] nicotinico
MX2010009876A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexanocarboxilico por medio del derivado de ciclohexanocarboxamida correspondiente.
EA201190256A1 (ru) Способ снижения уровня убиквитинилированных белков
WO2014128719A3 (en) Processes for the preparation of bispyribac sodium and intermediates thereof
EA201200765A1 (ru) Способ получения полиморфной модификации холиновой соли производного пиримидин-5-илуксусной кислоты